Premium
European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis
Author(s) -
Knobler R.,
Moinzadeh P.,
Hunzelmann N.,
Kreuter A.,
Cozzio A.,
Mouthon L.,
Cutolo M.,
Rongioletti F.,
Denton C.P.,
Rudnicka L.,
Frasin L.A.,
Smith V.,
Gabrielli A.,
Aberer E.,
Bagot M.,
Bali G.,
Bouaziz J.,
Braae Olesen A.,
Foeldvari I.,
Frances C.,
Jalili A.,
Just U.,
Kähäri V.,
Kárpáti S.,
Kofoed K.,
Krasowska D.,
Olszewska M.,
Orteu C.,
Panelius J.,
Parodi A.,
Petit A.,
Quaglino P.,
Ranki A.,
Sanchez Schmidt J.M.,
Seneschal J.,
Skrok A.,
Sticherling M.,
Sunderkötter C.,
Taieb A.,
Tanew A.,
Wolf P.,
Worm M.,
Wutte N.J.,
Krieg T.
Publication year - 2017
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.14466
Subject(s) - medicine , nephrogenic systemic fibrosis , dermatology , guideline , scleroderma (fungus) , differential diagnosis , pathology , magnetic resonance imaging , radiology , inoculation
The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first‐ and advanced‐line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).